{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:14:49Z","timestamp":1791213289591,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Dementia with Lewy bodies (DLB) is more prevalent in men than in women. In addition, post-mortem studies found sex differences in underlying pathology. It remains unclear whether these differences are also present antemortem in in vivo biomarkers, and whether sex differences translate to variability in clinical manifestation. The objective of this study was to evaluate sex differences in cerebrospinal fluid (CSF) biomarker concentrations (i.e., alpha-synuclein (\u03b1-syn), amyloid \u03b21-42 (A\u03b242), total tau (Tau), phosphorylated tau at threonine 181 (pTau)) and clinical characteristics in DLB.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We included 223 DLB patients from the Amsterdam Dementia Cohort, of which 39 were women (17%, age 70\u2009\u00b1\u20096, MMSE 21\u2009\u00b1\u20096) and 184 men (83%, age 68\u2009\u00b1\u20097, MMSE 23\u2009\u00b1\u20094). Sex differences in CSF biomarker concentrations (i.e., \u03b1-syn, A\u03b242, Tau, and pTau) were evaluated using age-corrected general linear models (GLM). In addition, we analyzed sex differences in core clinical features (i.e., visual hallucinations, parkinsonism, cognitive fluctuations, and REM sleep behavior disorder (RBD) and cognitive test scores using age- and education-adjusted GLM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Women had lower CSF \u03b1-syn levels (F 1429\u2009\u00b1\u2009164 vs M 1831\u2009\u00b1\u200960, <jats:italic>p<\/jats:italic>\u2009=\u20090.02) and CSF A\u03b242 levels (F 712\u2009\u00b1\u200939 vs M 821\u2009\u00b1\u200918, <jats:italic>p<\/jats:italic>\u2009=\u20090.01) compared to men. There were no sex differences for (p) Tau concentrations (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Clinically, women were older, had a shorter duration of complaints (F 2\u2009\u00b1\u20091 vs M 4\u2009\u00b1\u20093, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), more frequent hallucinations (58% vs 38%, <jats:italic>p<\/jats:italic>\u2009=\u20090.02), and scored lower on MMSE and a fluency task (MMSE, <jats:italic>p<\/jats:italic>\u2009=\u20090.02; animal fluency, <jats:italic>p<\/jats:italic>\u2009=\u20090.006). Men and women did not differ on fluctuations, RBD, parkinsonism, or other cognitive tests.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Women had lower A\u03b242 and \u03b1-syn levels than men, alongside a shorter duration of complaints. Moreover, at the time of diagnosis, women had lower cognitive test scores and more frequent hallucinations. Based on our findings, one could hypothesize that women have a more aggressive disease course in DLB compared to men. Future research should investigate whether women and men with DLB might benefit from sex-specific treatment strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13195-020-00610-9","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T14:04:05Z","timestamp":1587132245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies"],"prefix":"10.1186","volume":"12","author":[{"given":"M.","family":"van de Beek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Babapour Mofrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"van Steenoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Vanderstichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W.","family":"Lemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"issue":"1","key":"610_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"11","key":"610_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(11)70213-7","volume":"10","author":"K Vekrellis","year":"2011","unstructured":"Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of \u03b1-synuclein in neurological disorders. Lancet Neurol. 2011;10(11):1015\u201325.","journal-title":"Lancet Neurol"},{"issue":"1","key":"610_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JAD-160322","volume":"54","author":"I van Steenoven","year":"2016","unstructured":"van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, et al. Cerebrospinal fluid Alzheimer\u2019s disease biomarkers across the Spectrum of Lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis. 2016;54(1):287\u201395.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"610_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-018-0350-6","volume":"10","author":"JP Kane","year":"2018","unstructured":"Kane JP, Surendranathan A, Bentley A, Barker SA, Taylor J-P, Thomas AJ, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018;10(1):19.","journal-title":"Alzheimers Res Ther"},{"key":"610_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/NDT.S45840","volume":"9","author":"S-M Fereshtehnejad","year":"2013","unstructured":"Fereshtehnejad S-M, Religa D, Westman E, Aarsland D, L\u00f6kk J, Eriksdotter M. Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson\u2019s disease with dementia: data from the Swedish dementia quality registry (SveDem). Neuropsychiatr Dis Treat. 2013;9:927.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"610_CR6","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1001\/jamaneurol.2013.3579","volume":"70","author":"R Savica","year":"2013","unstructured":"Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396\u2013402.","journal-title":"JAMA Neurol"},{"issue":"4","key":"610_CR7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.31887\/DCNS.2016.18.4\/cepperson","volume":"18","author":"JL Podcasy","year":"2016","unstructured":"Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci. 2016;18(4):437.","journal-title":"Dialogues Clin Neurosci"},{"key":"610_CR8","doi-asserted-by":"publisher","unstructured":"Mouton A, Blanc F, Gros A, et al. Sex ratio in dementia with Lewy bodies balanced between Alzheimer\u2019s disease and Parkinson\u2019s disease dementia: a cross-sectional study. Alz Res Therapy. 2018;10:92. https:\/\/doi.org\/10.1186\/s13195-018-0417-4.","DOI":"10.1186\/s13195-018-0417-4"},{"key":"610_CR9","doi-asserted-by":"crossref","unstructured":"Price A, Farooq R, Yuan J-M, Menon VB, Cardinal RN, O\u2019Brien JT. Mortality in dementia with Lewy bodies compared with Alzheimer\u2019s dementia: a retrospective naturalistic cohort study. BMJ Open. 2017;7(11).","DOI":"10.1136\/bmjopen-2017-017504"},{"issue":"3","key":"610_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00415-009-5324-y","volume":"257","author":"PT Nelson","year":"2010","unstructured":"Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol. 2010;257(3):359\u201366.","journal-title":"J Neurol"},{"key":"610_CR11","doi-asserted-by":"crossref","unstructured":"Barnes LL, Lamar M, Schneider JA. Sex differences in mixed neuropathologies in community-dwelling older adults. Brain Res. 2019;1719:11-6.","DOI":"10.1016\/j.brainres.2019.05.028"},{"issue":"2","key":"610_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","volume":"88","author":"AW Lemstra","year":"2017","unstructured":"Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, et al. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2017;88(2):113\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"610_CR13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/mds.26668","volume":"31","author":"C Abdelnour","year":"2016","unstructured":"Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, et al. Alzheimer\u2019s disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. Mov Disord. 2016;31(8):1203\u20138.","journal-title":"Mov Disord"},{"issue":"8","key":"610_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2018.0821","volume":"75","author":"TJ Hohman","year":"2018","unstructured":"Hohman TJ, Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, et al. Sex-specific association of apolipoprotein e with cerebrospinal fluid levels of tau. JAMA Neurol. 2018;75(8):989\u201398.","journal-title":"JAMA Neurol"},{"issue":"6","key":"610_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archpsyc.62.6.685","volume":"62","author":"LL Barnes","year":"2005","unstructured":"Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62(6):685\u201391.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"610_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41582-018-0115-7","volume":"15","author":"RB Mofrad","year":"2019","unstructured":"Mofrad RB, van der Flier WM. Nature and implications of sex differences in AD pathology. Nat Rev Neurol. 2019;15(1):6.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"610_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/JAD-2012-111655","volume":"29","author":"M Wennstr\u00f6m","year":"2012","unstructured":"Wennstr\u00f6m M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and \u03b1-synuclein levels in dementia patients. J Alzheimers Dis. 2012;29(1):125\u201332.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"610_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/gps.4706","volume":"33","author":"PY Chiu","year":"2018","unstructured":"Chiu PY, Teng PR, Wei CY, Wang CW, Tsai CT. Gender difference in the association and presentation of visual hallucinations in dementia with Lewy bodies: a cross-sectional study. Int J Geriatr Psychiatry. 2018;33(1):193\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"610_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62(3):1091\u2013111.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"610_CR20","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"I McKeith","year":"2005","unstructured":"McKeith I, Dickson DW, Lowe J, Emre M, O'brien J, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies third report of the DLB consortium. Neurology. 2005;65(12):1863\u201372.","journal-title":"Neurology"},{"issue":"5 Suppl 6","key":"610_CR21","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","volume":"48","author":"JL Cummings","year":"1997","unstructured":"Cummings JL. The neuropsychiatric inventory assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):10S\u20136S.","journal-title":"Neurology"},{"key":"610_CR22","doi-asserted-by":"crossref","unstructured":"Sheikh JI, Yesavage JA. Geriatric depression scale (GDS): recent evidence and development of a shorter version. Clinical Gerontologist. J Aging Mental Health. 1986;5(1-2):165\u201373.","DOI":"10.1300\/J018v05n01_09"},{"key":"610_CR23","volume-title":"De 15-woordentest A en B (een voorlopige handleiding).","author":"R Saan","year":"1986","unstructured":"Saan R, Deelman B. De 15-woordentest A en B (een voorlopige handleiding). Groningen: Afdeling Neuropsychologie, AZG; 1986."},{"issue":"3","key":"610_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","volume":"8","author":"RM Reitan","year":"1958","unstructured":"Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271\u20136.","journal-title":"Percept Mot Skills"},{"key":"610_CR25","first-page":"108","volume":"8","author":"RB Mofrad","year":"2017","unstructured":"Mofrad RB, Bouwman FH, Slot RE, Timmers T, van der Flier WM, Scheltens P, et al. Lumbar puncture in patients with neurologic conditions. Alzheimers Dement. 2017;8:108\u201310.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"610_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2217\/bmm.12.46","volume":"6","author":"M Del Campo","year":"2012","unstructured":"Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6(4):419\u201330.","journal-title":"Biomark Med"},{"issue":"1","key":"610_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13195-017-0276-4","volume":"9","author":"D Chiasserini","year":"2017","unstructured":"Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, et al. Differential role of CSF fatty acid binding protein 3, \u03b1-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia. Alzheimers Res Ther. 2017;9(1):52.","journal-title":"Alzheimers Res Ther"},{"key":"610_CR28","first-page":"563","volume":"10","author":"EA Willemse","year":"2018","unstructured":"Willemse EA, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer\u2019s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. Alzheimers Dement. 2018;10:563\u201372.","journal-title":"Alzheimers Dement"},{"key":"610_CR29","first-page":"281055","volume":"2017","author":"BM Tijms","year":"2017","unstructured":"Tijms BM, Willemse EA, Zwan MD, Mulder SD, Visser PJ, van Berckel BN, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results. Clin Chem. 2017;2017:281055.","journal-title":"Clin Chem"},{"issue":"11","key":"610_CR30","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00415-010-5630-4","volume":"257","author":"PT Nelson","year":"2010","unstructured":"Nelson PT, Schmitt FA, Jicha GA, Kryscio RJ, Abner EL, Smith CD, et al. Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol. 2010;257(11):1875\u201381.","journal-title":"J Neurol"},{"issue":"21","key":"610_CR31","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between A\u03b2, tau, and \u03b1-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281\u20139.","journal-title":"J Neurosci"},{"issue":"9","key":"610_CR32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci. 2013;14(9):626.","journal-title":"Nat Rev Neurosci"},{"issue":"12","key":"610_CR33","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/NEN.0000000000000018","volume":"72","author":"M Colom-Cadena","year":"2013","unstructured":"Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Mart\u00ed MJ, et al. Confluence of \u03b1-synuclein, tau, and \u03b2-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2013;72(12):1203\u201312.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"610_CR34","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1212\/01.wnl.0000247041.63081.98","volume":"67","author":"MM Williams","year":"2006","unstructured":"Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67(11):1935\u201341.","journal-title":"Neurology."},{"issue":"7","key":"610_CR35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1440-1681.2007.04616.x","volume":"34","author":"B Liu","year":"2007","unstructured":"Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin Exp Pharmacol Physiol. 2007;34(7):555\u201365.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"610_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.expneurol.2009.03.003","volume":"217","author":"M Hirohata","year":"2009","unstructured":"Hirohata M, Ono K, Morinaga A, Ikeda T, Yamada M. Anti-aggregation and fibril-destabilizing effects of sex hormones on \u03b1-synuclein fibrils in vitro. Exp Neurol. 2009;217(2):434\u20139.","journal-title":"Exp Neurol"},{"issue":"26","key":"610_CR37","doi-asserted-by":"publisher","first-page":"26846","DOI":"10.1074\/jbc.M403129200","volume":"279","author":"M Zhu","year":"2004","unstructured":"Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of \u03b1-synuclein and disaggregates existing fibrils. J Biol Chem. 2004;279(26):26846\u201357.","journal-title":"J Biol Chem"},{"issue":"1","key":"610_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1471-4159.2006.03707.x","volume":"97","author":"K Ono","year":"2006","unstructured":"Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for \u03b1-synuclein fibrils in vitro. J Neurochem. 2006;97(1):105\u201315.","journal-title":"J Neurochem"},{"issue":"6","key":"610_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nsmb.1437","volume":"15","author":"DE Ehrnhoefer","year":"2008","unstructured":"Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15(6):558.","journal-title":"Nat Struct Mol Biol"},{"key":"610_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/CLEP.S37929","volume":"6","author":"MM Mielke","year":"2014","unstructured":"Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer\u2019s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37.","journal-title":"Clin Epidemiol"},{"issue":"10","key":"610_CR41","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000065889.42856.F2","volume":"60","author":"A Merdes","year":"2003","unstructured":"Merdes A, Hansen L, Jeste D, Galasko D, Hofstetter C, Ho G, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60(10):1586\u201390.","journal-title":"Neurology."},{"issue":"11","key":"610_CR42","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/mds.111","volume":"33","author":"I van Steenoven","year":"2018","unstructured":"van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WD, et al. \u03b1-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Mov Disord. 2018;33(11):1724\u201333.","journal-title":"Mov Disord"},{"issue":"40","key":"610_CR43","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson JP, Walker DE, Goldstein JM, De Laat R, Banducci K, Caccavello RJ, et al. Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281(40):29739\u201352.","journal-title":"J Biol Chem"},{"issue":"6","key":"610_CR44","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s00259-016-3312-x","volume":"43","author":"JJ van der Zande","year":"2016","unstructured":"van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW. [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2016;43(6):1060\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-020-00610-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T23:29:47Z","timestamp":1618615787000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00610-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00610-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"assertion":[{"value":"15 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all study participants for the use of clinical data and biomaterial for research purposes. This study was approved by the local medical ethical committee of the Amsterdam UMC, location VUmc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Dr. Teunissen has a collaboration contract with ADx Neurosciences and performed contract research or received grants from Probiodrug, AC Immune, Biogen-Esai, CogRx, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio, and Roche. Prof. Dr. Scheltens has acquired grant support (for the institution) from GE Healthcare and Piramal. In the past 2\u2009years, he has received consultancy\/speaker fees (paid to the institution) from Novartis, Probiodrug, Biogen, Roche, and EIP Pharma, LLC. Dr. Lemstra has received funding from stichting Dioraphte and ZonMW Memorabel (project #733050509). Research programs of Prof. Dr. Wiesje van der Flier have been funded by ZonMW, NWO, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Biogen MA Inc., Life-MI, AVID, and Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc. All funding is paid to her institution. Van de Beek, Babapour Mofrad, van Steenoven, Dr. vanderStichele report no disclosures relevant to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}